Peter Kolchinsky portfolio, Q4 2025

RA Capital Management · 13F for the quarter ending Dec 31, 2025

For Q4 2025, RA Capital Management reported $9.8B across 71 US-listed positions, led by ASND (22.5%), Cidara Therapeutics Inc (7.6%) and RYTM (7.3%). Compared with its filing for Q3 2025, Peter Kolchinsky opened 21 new positions, added to 13, reduced 8 and sold out of 17; 28 positions did not change.

The largest purchase was a new position in BCRX ($123.5M); the largest sale, the sale of the whole position in 89BIO Inc ($292.4M).

Reported value
$9.8B
Positions
71
In the top 10
66%
Filed
Feb 17
2026

Key facts

13F portfolio value
$9.8BQ4 2025
Positions
71
Largest holding
ASND 22.5%
New positions
21
Sold out
17
Filed
Feb 17, 2026

Holdings as of (Q4 2025), filed with the SEC on . Changes are measured against the filing for Sep 30, 2025. Every tracked investor's Q4 2025 13F.

Bought and sold in Q4 2025

Peter Kolchinsky: buys and sells in Q4 2025
StockMoveSharesSizeOf portfolio
89BIO Incno ticker on file
▼ Sold out−19.89M$292.4M3.00%
Climb Bio IncCLYM▼ Reduced 64%−20.13M$138.5M1.42%
BioCryst Pharmaceuticals IncBCRX▲ New+15.83M$123.5M1.26%
Arcellx Incno ticker on file
▼ Reduced 58%−1.77M$115.4M1.18%
Praxis Precision MedicinesPRAX▲ New+373.79K$110.2M1.13%
Rhythm Pharmaceuticals IncRYTM▲ Added 17%+985.48K$105.5M1.08%
Belite Bio IncBLTE▼ Reduced 51%−442.52K$70.8M0.73%
Olema Pharmaceuticals IncOLMA▲ New+2.6M$65M0.67%
Nuvalent Incno ticker on file
▲ Added 51%+633.6K$63.7M0.65%
Evommune IncEVMN▲ New+3.46M$59.2M0.61%
Vaxcyte IncPCVX▼ Reduced 10%−1.24M$57.3M0.59%
Spyre Therapeutics IncSYRE▲ New+1.62M$53.1M0.54%
Dianthus Therapeutics IncDNTH▼ Reduced 44%−1.26M$51.7M0.53%
Lexeo Therapeutics IncLXEO▲ New+5M$49.7M0.51%
Fulcrum Therapeutics IncFULC▼ Reduced 41%−4.18M$47.2M0.48%
Vor Biopharma IncVOR▲ Added 173%+3.42M$44.8M0.46%
Capricor Therapeutics IncCAPR▲ New+1.51M$43.5M0.45%
Scholar Rock Holding CorpSRRK▼ Sold out−1.17M$43.5M0.45%
Structure Therapeutics IncGPCR▼ Sold out−1.52M$42.5M0.44%
Jade Biosciences IncJBIO▲ Added 246%+2.61M$40.3M0.41%
Grail IncGRAL▲ New+428.27K$36.7M0.38%
Metsera Incno ticker on file
▼ Sold out−675.53K$35.4M0.36%
Disc Medicine IncIRON▲ Added 25%+399.03K$31.7M0.32%
Travere Therapeutics IncTVTX▼ Sold out−1.15M$27.5M0.28%
Benitec Biopharma IncBNTC▲ New+1.85M$24.9M0.26%
Sionna Therapeutics IncSION▼ Reduced 5.2%−540.28K$22.2M0.23%
Rezolute IncRZLT▲ New+9.18M$21.7M0.22%
Newamsterdam Pharma CompanyNAMS▼ Reduced 5.8%−588.75K$20.7M0.21%
Larimar Therapeutics IncLRMR▼ Sold out−6.05M$19.5M0.20%
Ovid Therapeutics IncOVID▲ New+10.71M$17.5M0.18%
Tango Therapeutics IncTNGX▼ Sold out−2M$16.8M0.17%
Palisade Bio IncPALI▲ New+7.12M$16.7M0.17%
Prime Medicine IncPRME▼ Sold out−3M$16.6M0.17%
Arcus Biosciences IncRCUS▼ Sold out−1.14M$15.5M0.16%
C4 Therapeutics IncCCCC▲ New+8M$15.3M0.16%
Medline IncMDLN▲ New+335K$14.1M0.14%
Uniqure NVQURE▼ Sold out−200K$11.7M0.12%
Rani Therapeutics Holdings-ARANI▲ New+8.5M$11.5M0.12%
Monopar Therapeutics IncMNPR▲ Added 31%+156K$10.2M0.10%
LB Pharmaceuticals IncLBRX▲ Added 24%+431.65K$9.6M0.10%
Design Therapeutics IncDSGN▲ Added 207%+985.68K$9.2M0.09%
Eledon Pharmaceuticals IncELDN▼ Sold out−3.57M$9.2M0.09%
CytomX Therapeutics IncCTMX▼ Sold out−2.66M$8.5M0.09%
4D Molecular TherapeuticsFDMT▲ Added 24%+1.09M$8.2M0.08%
Surrozen IncSRZN▼ Sold out−602.63K$7.8M0.08%
Evolent Health IncEVH▼ Sold out−579.05K$4.9M0.05%
Waystar Holding CorpWAY▲ New+144.4K$4.7M0.05%
Geron CorpGERN▲ Added 5.6%+3.39M$4.5M0.05%
Glaukos CorpGKOS▼ Sold out−54.18K$4.4M0.05%
Hinge Health IncHNGE▲ New+80.11K$3.7M0.04%
Exact Sciences Corpno ticker on file
▼ Sold out−54.94K$3M0.03%
Inflarx NVIFRX▼ Sold out−1.97M$2.6M0.03%
Inspire Med Systems IncINSP▲ Added 24%+27.06K$2.5M0.03%
Qiagen NVQGEN▲ New+43.98K$2.1M0.02%
Orthopediatrics CorpKIDS▲ New+109.96K$2M0.02%
Health Catalyst IncHCAT▲ New+793.75K$1.9M0.02%
Palatin Technologies IncPTN▲ New+70K$1.1M0.01%
Contineum Therapeutics IncCTNM▲ Added 2.7%+57.71K$659.6K0.01%
Wave Life Sciences LtdWVE▲ Added 0.01%+1K$17K0.00%

Holdings at the quarter's end

Peter Kolchinsky holdings, Q4 2025
#StockSectorShare of portfolioValueSharesReported priceHeldSince Q3 2025
1Ascendis Pharma A/SASND · SPONSORED ADRHealth Care22.5%$2.2B10.28M$213.247+ qtrsNo change
2
Cidara Therapeutics Incno ticker on file · SH
—7.62%$743.4M3.37M$220.896 qtrsNo change
3Rhythm Pharmaceuticals IncRYTMHealth Care7.31%$713.6M6.67M$107.047+ qtrs▲ Added 17%
4
Avidity Biosciences Incno ticker on file · SH
—6.39%$623.3M8.64M$72.137+ qtrsNo change
5Vaxcyte IncPCVXHealth Care5.07%$494.8M10.72M$46.147+ qtrs▼ Reduced 10%
6Sionna Therapeutics IncSION—4.18%$407.5M9.91M$41.144 qtrs▼ Reduced 5.2%
7Newamsterdam Pharma CompanyNAMS—3.43%$335M9.55M$35.087+ qtrs▼ Reduced 5.8%
8Tyra Biosciences IncTYRA—3.29%$320.7M12.2M$26.297+ qtrsNo change
9Wave Life Sciences LtdWVE—3.17%$309.5M18.2M$17.007+ qtrs▲ Added 0.01%
10Mineralys Therapeutics IncMLYS—2.72%$265.8M7.32M$36.297+ qtrsNo change
11Edgewise Therapeutics IncEWTXHealth Care2.65%$258.8M10.43M$24.817+ qtrsNo change
12Septerna IncSEPN—2.00%$195M7M$27.885 qtrsNo change
13
Nuvalent Incno ticker on file
—1.94%$189.1M1.88M$100.592 qtrs▲ Added 51%
14Disc Medicine IncIRON—1.61%$156.9M1.98M$79.414 qtrs▲ Added 25%
15Janux Therapeutics IncJANX—1.58%$154.4M11.19M$13.807+ qtrsNo change
16Pepgen IncPEPG—1.34%$130.6M20.06M$6.517+ qtrsNo change
17Taysha Gene Therapies IncTSHA—1.33%$129.6M23.56M$5.507+ qtrsNo change
18Ars Pharmaceuticals IncSPRY—1.30%$126.5M10.86M$11.657+ qtrsNo change
19BioCryst Pharmaceuticals IncBCRX—1.27%$123.5M15.83M$7.801 qtrNew
20Bicara Therapeutics IncBCAX—1.20%$117.1M6.96M$16.836 qtrsNo change
21Praxis Precision MedicinesPRAXHealth Care1.13%$110.2M373.79K$294.741 qtrNew
22GH Research PLCGHRS—1.00%$97.5M7.68M$12.707+ qtrsNo change
23Geron CorpGERN—0.86%$84.2M63.77M$1.327+ qtrs▲ Added 5.6%
24
Arcellx Incno ticker on file · SH
—0.85%$82.6M1.27M$65.207+ qtrs▼ Reduced 58%
25Climb Bio IncCLYM—0.80%$77.7M11.29M$6.887+ qtrs▼ Reduced 64%
26Vor Biopharma IncVOR—0.72%$70.7M5.4M$13.087+ qtrs▲ Added 173%
27Belite Bio IncBLTE · SHHealth Care0.71%$69.2M432.48K$159.962 qtrs▼ Reduced 51%
28Fulcrum Therapeutics IncFULC—0.70%$68.5M6.05M$11.317+ qtrs▼ Reduced 41%
29Lenz Therapeutics IncLENZ—0.69%$66.9M4.18M$16.007+ qtrsNo change
30Dianthus Therapeutics IncDNTHHealth Care0.68%$66.4M1.61M$41.217+ qtrs▼ Reduced 44%
31Olema Pharmaceuticals IncOLMA—0.67%$65M2.6M$25.001 qtrNew
32Evommune IncEVMN—0.61%$59.2M3.46M$17.121 qtrNew
33Jade Biosciences IncJBIO—0.58%$56.6M3.67M$15.433 qtrs▲ Added 246%
34Spyre Therapeutics IncSYREHealth Care0.54%$53.1M1.62M$32.761 qtrNew
35Lexeo Therapeutics IncLXEO—0.51%$49.7M5M$9.931 qtrNew
36LB Pharmaceuticals IncLBRX—0.50%$49.2M2.21M$22.262 qtrs▲ Added 24%
37Monopar Therapeutics IncMNPR—0.45%$43.6M667.21K$65.305 qtrs▲ Added 31%
38Capricor Therapeutics IncCAPR—0.45%$43.5M1.51M$28.861 qtrNew
394D Molecular TherapeuticsFDMT—0.43%$42.4M5.65M$7.507+ qtrs▲ Added 24%
40Invivyd IncIVVD · SH—0.43%$42.3M17.12M$2.472 qtrsNo change
41Artiva Biotherapeutics IncARTV—0.43%$42.3M9.85M$4.296 qtrsNo change
42Grail IncGRALHealth Care0.38%$36.7M428.27K$85.591 qtrNew
43Assembly Biosciences IncASMB—0.36%$34.7M1.02M$34.012 qtrsNo change
44Solid Biosciences IncSLDB—0.34%$32.8M5.81M$5.647+ qtrsNo change
45Acumen Pharmaceuticals IncABOS—0.32%$31.5M14.93M$2.117+ qtrsNo change
46Benitec Biopharma IncBNTC—0.26%$24.9M1.85M$13.471 qtrNew
47Contineum Therapeutics IncCTNM—0.26%$24.9M2.18M$11.432 qtrs▲ Added 2.7%
48Rezolute IncRZLT—0.22%$21.7M9.18M$2.361 qtrNew
49Acrivon Therapeutics IncACRV—0.21%$20.1M8.34M$2.417+ qtrsNo change
50Nkarta IncNKTX—0.21%$20M10.81M$1.857+ qtrsNo change
51Ovid Therapeutics IncOVID—0.18%$17.5M10.71M$1.631 qtrNew
52Palisade Bio IncPALI—0.17%$16.7M7.12M$2.351 qtrNew
53Sab Biotherapeutics IncSABS—0.17%$16.5M4.4M$3.742 qtrsNo change
54C4 Therapeutics IncCCCC—0.16%$15.3M8M$1.911 qtrNew
55Medline IncMDLN · SHHealth Care0.14%$14.1M335K$42.001 qtrNew
56Design Therapeutics IncDSGN—0.14%$13.7M1.46M$9.382 qtrs▲ Added 207%
57Inspire Med Systems IncINSP—0.13%$13.1M141.96K$92.232 qtrs▲ Added 24%
58Avalo Therapeutics IncAVTX—0.12%$12M662.97K$18.166 qtrsNo change
59Rani Therapeutics Holdings-ARANI—0.12%$11.5M8.5M$1.351 qtrNew
60
Perceptive Cap Solutionsno ticker on file
—0.10%$9.8M750K$13.037+ qtrsNo change
61Adicet Bio IncACET—0.08%$8M948.25K$8.427+ qtrs—
62
Newamsterdam Pharma Co NV-27no ticker on file · WTS
—0.08%$7.7M333.33K$23.007+ qtrsNo change
63GeneDx Holdings CorpWGS—0.08%$7.5M58.04K$130.063 qtrsNo change
64Waystar Holding CorpWAYTechnology0.05%$4.7M144.4K$32.751 qtrNew
65Werewolf Therapeutics IncHOWL—0.04%$4.2M6.68M$0.63357+ qtrsNo change
66Hinge Health IncHNGETechnology0.04%$3.7M80.11K$46.451 qtrNew
67Progyny IncPGNY · SH—0.03%$2.5M96.63K$25.682 qtrsNo change
68Qiagen NVQGEN · SHHealth Care0.02%$2.1M43.98K$47.341 qtrNew
69Orthopediatrics CorpKIDS · SH—0.02%$2M109.96K$17.761 qtrNew
70Health Catalyst IncHCAT · SH—0.02%$1.9M793.75K$2.391 qtrNew
71Palatin Technologies IncPTN—0.01%$1.1M70K$15.381 qtrNew

By sector

Peter Kolchinsky portfolio by sector, Q4 2025
SectorShare of portfolioValuePositions
Health Care41.1%$4B11
Technology0.09%$8.5M2
No sector on file58.8%$5.7B58

Questions and answers

What did Peter Kolchinsky own in Q4 2025?

RA Capital Management's 13F for Q4 2025 lists 71 positions worth $9.8B. The largest: ASND (22.5%), Cidara Therapeutics Inc (7.6%), RYTM (7.3%), Avidity Biosciences Inc (6.4%), PCVX (5.1%).

What did Peter Kolchinsky buy in Q4 2025?

The largest purchases, by the shares bought at the quarter-end price the filing implies: BCRX (new, $123.5M), PRAX (new, $110.2M), RYTM (added, $105.5M), OLMA (new, $65M), Nuvalent Inc (added, $63.7M), EVMN (new, $59.2M).

What did Peter Kolchinsky sell in Q4 2025?

The largest sales: 89BIO Inc (sold out, $292.4M), CLYM (reduced, $138.5M), Arcellx Inc (reduced, $115.4M), BLTE (reduced, $70.8M), PCVX (reduced, $57.3M), DNTH (reduced, $51.7M).

When was this filing made?

RA Capital Management filed its 13F for the quarter ending Dec 31, 2025 on Feb 17, 2026. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.

Learn

Cite this page

Funkfolio, “Peter Kolchinsky portfolio, Q4 2025: RA Capital Management 13F holdings”, data as of 17 February 2026. https://funkfolio.com/gurus/peter-kolchinsky/2025-q4

Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Dec 31, 2025.

Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Dec 31, 2025, filed Feb 17, 2026. Changes compare share counts with the filing for Sep 30, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $9.8B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 7 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.